BLA filing, new clinical trials) is futile In m

Quote:

---

BLA filing, new clinical trials) is futile

---

In my opinion, the BLA filing will be the most significant event in CytoDyn's history. Before the submission, there is a possible the company runs out of cash before the BLA is filed, which would be a complete mess for say anyone buying out the company in a fire sale. After the BLA submission, they could shut everything down and wait on drug approval, sell leronlimab after approval and get more than the current market cap. With each BLA delay announcement the share price has dropped, as I feel the market has assumed the probability increased the BLA submission being delayed even more. Finally finishing the BLA is very significant event in my opinion, especially since that moves the very predictable cydy announcements to the unpredictable timing on the FDA drug approval announcement. I see many traders buy on that rumor of approval and I have seen the share price increase of other companies as they await the fda decision in the anticipation of approval. I'm looking forward to seeing if the market sees it that way.